Kalpataru Multiplier Ltd.

Our Bank & DP Click for Online Payment MF portfolio login smart way to invest in gold
Sovereign gold bond(SGB) Exchange trades funds(ETF)
CLOSE

Download our app Kalpataru Share trading from Google/App Store and transfer fund instantly.

Company Profile
more from company profile
HomeMarkets Company Profile Smart Quotes

Smart Quotes

JENBURKT PHARMACEUTICALS LTD.

NSE : NABSE : 524731ISIN CODE : INE354A01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE799.8513.35 (+1.7 %)
PREV CLOSE () 786.50
OPEN PRICE () 778.10
BID PRICE (QTY) 790.75 (31)
OFFER PRICE (QTY) 798.95 (5)
VOLUME 504
TODAY'S LOW / HIGH ()778.10 799.85
52 WK LOW / HIGH () 586.9925
NSE
This Company is not listed in NSE
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 1985

Management Info :

Ashish U Bhuta - Chairman Ashish U Bhuta - Managing Director

Registered Office :

Address : Nirmala Apartments,93 Jayprakash Road,Andheri (West),
Mumbai,
Maharashtra-400058

Phone : 022-67603603

Website : www.jenburkt.com

Registrar's Details : Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE
NEWS
02Mar Jenburkt Pharmaceuticals informs about
In terms of Regulation 39(3) of the Securities and Exchange Board of Ind..
13Dec Jenburkt Pharmaceuticals informs about
Jenburkt Pharmaceuticals has informed that the information received from..
09Aug Jenburkt Pharmaceuticals informs about
Pursuant to Regulation 39(3) of the Securities and Exchange Board of Ind..
14Jul Jenburkt Pharmaceuticals informs about
Pursuant to Regulation 39(3) of the Securities and Exchange Board of Ind..
07Jul Jenburkt Pharmaceuticals informs about
Pursuant to Regulation 39(3) of the Securities and Exchange Board of Ind..
Financials
in Millions
QTR Dec 23 ANNUAL 23
Net Profit54.03246.06
Gross Profit 78.39 328.64
Operating Profit 85.39354.9
Net Sales 356.61367.49
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Sanofi India (BSE)
 8910.00 (3.96%)
M.Cap ( in Cr)
20289.98
Astrazeneca Pharma I (BSE)
 5795.00 (2.76%)
M.Cap ( in Cr)
14220.00
Pfizer (BSE)
 4396.10 (1.39%)
M.Cap ( in Cr)
19966.37
Mankind Pharma (BSE)
 2124.45 (1.55%)
M.Cap ( in Cr)
85415.41
Alkem Laboratories (BSE)
 5341.40 (0.46%)
M.Cap ( in Cr)
63322.22
Shareholding Pattern
NON-INSTITUTION 52.77%
PROMOTERS 47.23%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
Mf Holding
Scheme NameHold(%)
No Data Found
ATTENTION INVESTORS

Kalpataru Multiplier Ltd.

Kalpataru is a wishful Divine Tree and in present context a widely Trusted, Time tested and Transparent Share Broker, Mutual Fund Distributor and D.P. of this region.

Mobile Trading App
Mobile Trading IOS App
Call Us 0755-4350141/142/143, 9425008895
Mutual Funds 0755-4276725, 4276726
Email Uskmlho@kalpatarumulti.com

registration nos:

Kalpataru Multiplier Ltd.: SEBI Regn. No. INZ000259437

Registered address: Kalpataru House, 18 Itwara, Bhopal (MP) – 462001

Member Member ID
Bombay Stock Exchange Ltd.(BSE) 3016
National Stock Exchange Ltd. 11152
Multi Commodity Exchange(MCX) 16020

Depository Participant of CDSL DP-ID 12031600

(SEBI Regn No. IN-DP-CDSL-221-2003)

In absence of response/ complaint not addressed to your satisfaction, you may lodge a complaint and reach out to us on:

SMART ODR PORTAL @ https://smartodr.in/login

Copyright © 2016 Kalparatu Multiplier Ltd.
Designed ,Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
SENSEX73838.06174.34 (0.24%)
NIFTY22410.606.75 (0.03%)
Dow Jones 39908.00349.89 (0.88%)
Nasdaq 16742.39231.21 (1.40%)
CLOSE Disclosure
CLOSE

INFORMATION UNDER THE HEAD SHOULD BE ADDED AS FOLLOWS

  • Sharing of trading credentials - login id & password including OTP's.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing / selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through Whatsapp, Telegram, YouTube, Facebook, SMS, Calls, etc.
  • Trading in "Options" based on recommendations from unauthorised / unregistered investment advisors and influencers.
CLOSE SEBI